IMUNON Announces New Immunogenicity Data from Phase 1 Clinical Trial of Its DNA Vaccine in Treatment of COVID-19
Results of IMNN-101 Proof-of-Concept study demonstrate persistent immunogenicity in trial participants and further validate PlaCCine® ...
Imunon, Inc.: IMUNON Announces New Immunogenicity Data from Phase 1 Clinical Trial of Its DNA Vaccine in Treatment of COVID-19
Results of IMNN-101 Proof-of-Concept study demonstrate persistent immunogenicity in trial participants and further validate PlaCCine® technology IMNN-101 induced 2- to 4-fold increase in neutralizing ...
Korro to Present at the TD Cowen 45th Annual Health Care Conference
A live webcast of the presentation can be accessed on the “Events & Presentations” page in the Investor section of Korro’s website at www.korrobio.com. Following the presentation, a replay of the ...
Groundbreaking New Vaccine Claims To Reverse Cancer In Those With the Fatal Disease; Here's How
A groundbreaking vaccine has been able to reverse cancer in nine patients, part of a trial, who received tailor-made jabs ...